After curative-intent surgery for colorectal cancer, conventional clinicopathologic features may not fully capture the risk of recurrence. Circulating tumor DNA (ctDNA) is being investigated as a blood-based marker that may help detect persistent tumor burden before it becomes radiologically apparent. Reference: Nature Medicine (Scroll down to answer the question) ##Disclaimer## The content provided on Docplexus is intended for educational purposes only.

While we strive to ensure its accuracy, we make no warranties, explicit or implied, about the suitability, reliability, or adequacy of the information, including data visualization elements and graphics. We do not endorse any medical treatment, product, ideas, or service, including content from our industry partners. We do not associate with the views of any individual, community, organization, industry partner, or political party.…